Patents by Inventor Nathalie Guillo

Nathalie Guillo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10772946
    Abstract: The invention relates to a conjugate of a saccharide covalently bound to a carrier protein, wherein the saccharide comprises repetitive units of 1,5 ribitol phosphate in which all the ribitol residues are substituted by N-acetyl D-glucosaminyl residues at the 4-position, and wherein said N-acetyl D-glucosaminyl residues are exclusively in anomeric configuration ? or are exclusively in anomeric configuration ? and wherein the carrier protein provides at least one epitope to the conjugate which is recognized by T helper lymphocytes.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: September 15, 2020
    Assignee: SANOFI PASTEUR
    Inventors: Pierre-Alexandre Driguez, Nathalie Guillo, Bachra Rokbi, Noëlle Mistretta, Philippe Talaga
  • Publication number: 20180280491
    Abstract: The invention relates to a conjugate of a saccharide covalently bound to a carrier protein, wherein the saccharide comprises repetitive units of 1,5 ribitol phosphate in which all the ribitol residues are substituted by N-acetyl D-glucosaminyl residues at the 4-position, and wherein said N-acetyl D-glucosaminyl residues are exclusively in anomeric configuration ? or are exclusively in anomeric configuration ? and wherein the carrier protein provides at least one epitope to the conjugate which is recognized by T helper lymphocytes.
    Type: Application
    Filed: October 13, 2016
    Publication date: October 4, 2018
    Applicant: SANOFI PASTEUR
    Inventors: Pierre-Alexandre DRIGUEZ, Nathalie GUILLO, Bachra ROKBI, Noëlle MISTRETTA, Philippe TALAGA
  • Patent number: 9856257
    Abstract: The invention related to pyrazolonaphthyridinone derivatives of formula (I) to their preparation and to their therapeutic use as selective inhibitors of type 2 methionine aminopeptidase (hMETAP2).
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: January 2, 2018
    Assignee: SANOFI
    Inventors: Nathalie Guillo, Valérie Martin
  • Publication number: 20160060265
    Abstract: The invention related to pyrazolonaphthyridinone derivatives of formula (I) to their preparation and to their therapeutic use as selective inhibitors of type 2 methionine aminopeptidase (hMETAP2).
    Type: Application
    Filed: March 21, 2014
    Publication date: March 3, 2016
    Inventors: Nathalie GUILLO, Valérie MARTIN
  • Patent number: 9206177
    Abstract: The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce FGFR dimerization, having the general formula: M-L-M2 in which M and M2, which may be identical or different, each represent, independently of one another, a monomer unit M and L represents a linker group which links M1 and M2 covalently with the monomer unit which follows (Formula M). Process for the preparation thereof and therapeutic use thereof.
    Type: Grant
    Filed: December 26, 2012
    Date of Patent: December 8, 2015
    Assignee: SANOFI
    Inventors: Alexandre Benazet, Nathalie Guillo
  • Patent number: 9169246
    Abstract: The invention relates to compounds corresponding to formula (I) in which R1, R2 and R3 are as defined in Claim 1, and also to the process for preparing them and to their therapeutic use.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: October 27, 2015
    Assignee: SANOFI
    Inventors: Alexandre Benazet, Olivier Duclos, Nathalie Guillo, Gilbert Lassalle, Karim Macary, Valérie Vin
  • Patent number: 9120819
    Abstract: FGF receptor agonist compounds corresponding to the general formula: M1-L-M2 are disclosed in which M1 and M2, which may be identical or different, each represent, independently of one another, a monomer unit M, and L represents a linker group, wherein the monomer unit is of the general formula I.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: September 1, 2015
    Assignee: SANOFI
    Inventors: Francoise Bono, Nathalie Guillo, Jean-Pierre Maffrand, Pierre Fons, Jacob-Alsboek Olsen, Gilles Anne-Archard
  • Patent number: 9034898
    Abstract: The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce fibroblast growth factor receptor (FGFR) dimerization, having the general formula: M1-L-M2 in which M1 or M2, which may be identical or different, each represent, independently of one another, a monomer unit M and L represents a linker group which links M1 and M2 covalently with the monomer unit which follows: Process for the preparation thereof and therapeutic use thereof.
    Type: Grant
    Filed: December 26, 2012
    Date of Patent: May 19, 2015
    Inventors: Marie-Line Clary-Ceccato, Nathalie Guillo
  • Publication number: 20150011579
    Abstract: The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce fibroblast growth factor receptor (FGFR) dimerization, having the general formula: M1-L-M2 in which M1 or M2, which may be identical or different, each represent, independently of one another, a monomer unit M and L represents a linker group which links M1 and M2 covalently with the monomer unit which follows: Process for the preparation thereof and therapeutic use thereof.
    Type: Application
    Filed: December 26, 2012
    Publication date: January 8, 2015
    Inventors: Marie-Line Clary-Ceccato, Nathalie Guillo
  • Publication number: 20140378483
    Abstract: The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce FGFR dimerization, having the general formula: M-L-M2 in which M and M2, which may be identical or different, each represent, independently of one another, a monomer unit M and L represents a linker group which links M1 and M2 covalently with the monomer unit which follows (Formula M). Process for the preparation thereof and therapeutic use thereof.
    Type: Application
    Filed: December 26, 2012
    Publication date: December 25, 2014
    Inventors: Alexandre Benazet, Nathalie Guillo
  • Publication number: 20140235616
    Abstract: The invention relates to compounds corresponding to formula (I), in which R1, R2 and R3 are as defined in Claim 1, and also to the process for preparing them and to their therapeutic use.
    Type: Application
    Filed: September 24, 2012
    Publication date: August 21, 2014
    Applicant: SANOFI
    Inventors: Alexandre Benazet, Olivier Duclos, Nathalie Guillo, Gilbert Lassalle, Karim Macary, Valerie Vin
  • Publication number: 20130079337
    Abstract: The invention relates to compounds corresponding to formula (I) in which R1, R2 and R3 are as defined in Claim 1, and also to the process for preparing them and to their therapeutic use.
    Type: Application
    Filed: September 26, 2011
    Publication date: March 28, 2013
    Applicant: SANOFI
    Inventors: ALEXANDRE BENAZET, OLIVIER DUCLOS, NATHALIE GUILLO, GILBERT LASSALLE, KARIM MACARY, VALÉRIE VIN
  • Patent number: 8034828
    Abstract: The present invention thus relates to the use of 1,2,3-substituted indolizine derivatives in the preparation of medicaments of use in the treatment of diseases related to pathological choroidal angiogenesis, which derivatives correspond to the following general formula (I):
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: October 11, 2011
    Assignee: Sanofi-Aventis
    Inventors: Alain Badorc, Francoise Bono, Marie-Francoise Bordes, Jean-Michel Foidart, Nathalie Guillo, Agnes Noel, Jean-Marie Rakic
  • Patent number: 7803811
    Abstract: The present invention relates to novel 1,2,3-substituted indolizine derivative which are inhibitors of fibroblast growth factors, to methods or preparing such derivatives, to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising such derivatives.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: September 28, 2010
    Assignee: Sanofi-Aventis
    Inventors: Alain Badorc, Francoise Bono, Marie-Francoise Bordes, Nathalie Guillo, Jean-Marc Herbert
  • Patent number: 7553845
    Abstract: The invention is directed to a compound of formula I, wherein R, R1, R2, R3 and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, and its pharmaceutically composition, preparation and uses as an inhibitor of FGFs (fibroblast growth factors).
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: June 30, 2009
    Assignee: sanofi-aventis
    Inventors: Chantal Alcouffe, Alain Badorc, Francoise Bono, Marie-Francoise Bordes, Nathalie Guillo, Jean-Marc Herbert
  • Publication number: 20090069368
    Abstract: FGF receptor agonist compounds corresponding to the general formula: M1-L-M2 are disclosed in which M1 and M2, which may be identical or different, each represent, independently of one another, a monomer unit M, and L represents a linker group, wherein the monomer unit is of the general formula I.
    Type: Application
    Filed: July 11, 2008
    Publication date: March 12, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Francoise BONO, Nathalie GUILLO, Jean-Pierre MAFFRAND, Pierre FONS, Jacob-Alsboek OLSEN, Gilles ANNE-ARCHARD
  • Publication number: 20090030034
    Abstract: The present invention thus relates to the use of 1,2,3-substituted indolizine derivatives in the preparation of medicaments of use in the treatment of diseases related to pathological choroidal angiogenesis, which derivatives correspond to the following general formula (I):
    Type: Application
    Filed: August 29, 2008
    Publication date: January 29, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Alain BADORC, Francoise BONO, Marie-Francoise BORDES, Jean-Michel FOIDART, Nathalie GUILLO, Agnes NOEL, Jean Marie RAKIC
  • Publication number: 20090023770
    Abstract: The present invention relates to novel 1,2,3-substituted indolizine derivative which are inhibitors of fibroblast growth factors, to methods or preparing such derivatives, to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising such derivatives.
    Type: Application
    Filed: August 26, 2008
    Publication date: January 22, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Alain BADORC, Francoise BONO, Marie-Francoise BORDES, Nathalie GUILLO, Jean-Marc HERBERT
  • Patent number: 7442708
    Abstract: Compounds of formula I or salts thereof: in which R1 represents —OH, (C1-C5)alkoxy, carboxyl, (C2-C6)alkoxycarbonyl, —NR5R6, —NH—SO2-Alk, —NH—SO2-Ph, —NH—CO-Ph, —N(Alk)-CO-Ph, —NH—CO—NH-Ph, —NH—CO-Alk, —NH—CO2-Alk, —O—(CH2)n-cAlk, —O-Alk-COOR7, —O-Alk-O—R8, —O-Alk-OH, —O-Alk-C(NH2):NOH, —O-Alk-NR5R6, —O-Alk-CN, —O—(CH2)n-Ph, —O-Alk-CO—NR5R6, —CO—NH—(CH2)m—COOR7, —CO—NH-Alk R2 represents H, (C1-C5)alkyl, (C1-C5)alkyl halide, (C3-C6)cycloalkyl or phenyl which is optionally substituted, A represents —CO—, —SO— or —SO2—, R3 and R4 which are identical or different, each represent H, (C1-C5)alkoxy, amino, carboxyl, (C2-C6)alkoxycarbonyl, —OH, nitro, hydroxyamino, -Alk-COOR7, —NR5R6, —NH-Alk-COOR7, —NH—COO-Alk, —N(R11)—SO2-Alk-NR9R10, —N(R11)—SO2-Alk, —N(R11)-Alk-NR5R6, —N(R11)—CO-Alk-NR9R10, —N(R11)—CO-Alk, —N(R11)—CO—CF3, —NH-Alk-HetN, —O-Alk-NR9R10, —O-Alk-CO—NR5R6, —O-Alk-HetN, or R3 and R4 form together a 5- to 6-membered unsaturated heterocycle, are inhibitors of basic fibroblast growth factors.
    Type: Grant
    Filed: April 2, 2003
    Date of Patent: October 28, 2008
    Assignee: Sanofi-Aventis
    Inventors: Alain Badorc, Francoise Bono, Marie-Francoise Bordes, Nathalie Guillo, Jean-Marc Herbert
  • Publication number: 20060199962
    Abstract: The invention is directed to a compound of formula I, wherein R, R1, R2, R3 and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, and its pharmaceutically composition, preparation and uses as an inhibitor of FGFs (fibroblast growth factors).
    Type: Application
    Filed: March 17, 2006
    Publication date: September 7, 2006
    Applicant: Sanofi-aventis
    Inventors: Chantal Alcouffe, Alain Badorc, Francoise Bono, Marie-Francoise Bordes, Nathalie Guillo, Jean-Marc Herbert